- Stocks
- Pharma & Healthcare
- Gaudium IVF and Women Health
Gaudium IVF and Women Health share price
NSE: GAUDIUMIVFPharma & HealthcareMedical Care Facilities
Gaudium IVF and Women Health at a glance
Gaudium IVF and Women Health (NSE: GAUDIUMIVF) closed at ₹95.11 on 22 Oct 2026, up 1.07% on the day. With a market capitalisation of ₹692 Cr, it ranks 1635th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Care Facilities.
At its last close the stock traded at 24.3× trailing earnings, against a return on equity of 16.1% in FY26. Its 52-week range is ₹69.18 (23 Mar 2026) to ₹163.18 (22 Jul 2026); the last close is 41.7% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹30 Cr (+12.7% year on year) and net profit ₹8 Cr (+29.6%), on a consolidated basis. Promoters held 71.29% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹692 CrRank 1635 on NSE
- P/E (trailing)
- 24.3×
- Price to book
- 3.41×FY26
- EPS (TTM)
- ₹3.97to Q4 FY26
- ROE
- 16.1%FY26
- ROCE
- 23.1%FY26
- Debt to equity
- 0.15FY26
- Net profit margin
- 23.4%FY26
- Book value / share
- ₹20.92FY26
- 52-week high
- ₹163.1822 Jul 2026
- 52-week low
- ₹69.1823 Mar 2026
- RSI (14-day)
- 29.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | +1.07% | −9.0% | −14.8% | −39.0% | — |
Gaudium IVF and Women Health quarterly results
| Quarter | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹14 Cr | ₹27 Cr | ₹18 Cr | ₹32 Cr | ₹25 Cr | ₹30 Cr |
| Revenue YoY | — | — | — | — | +70.0% | +12.7% |
| Net profit | ₹3 Cr | ₹6 Cr | ₹3 Cr | ₹9 Cr | ₹4 Cr | ₹8 Cr |
| Net profit YoY | — | — | — | — | +6.8% | +29.6% |
| Net margin | 23.6% | 24.0% | 17.6% | 29.6% | 14.8% | 27.5% |
| EPS | ₹0.55 | ₹1.05 | ₹0.51 | ₹1.53 | ₹0.59 | ₹1.34 |
Gaudium IVF and Women Health financials
| Item | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|
| Revenue | ₹44 Cr | ₹48 Cr | ₹71 Cr | — |
| Operating profit | ₹18 Cr | ₹17 Cr | ₹25 Cr | — |
| Net profit | ₹14 Cr | ₹10 Cr | ₹19 Cr | — |
| EPS (₹) | ₹2.00 | ₹2.00 | ₹3.00 | — |
| Cash from operations | ₹24 Cr | ₹3 Cr | ₹9 Cr | — |
| Total debt | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹0 Cr |
| Shareholders' equity | ₹23 Cr | ₹27 Cr | ₹46 Cr | ₹152 Cr |
Gaudium IVF and Women Health shareholding pattern
| Holder | 26 Feb 2026 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|
| Promoters | 71.29% | 71.29% | 71.29% |
| Foreign institutions | 9.24% | 6.70% | 3.02% |
| Domestic institutions | 5.11% | 2.62% | 2.22% |
| Non-institutions | 14.36% | 19.39% | 23.47% |
Gaudium IVF and Women Health vs peers
The listed Pharma & Healthcare companies nearest to Gaudium IVF and Women Health by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KILITCHKilitch Drugs (India) | ₹215.00 | −0.92% | +22.8% | ₹752 Cr | 24.2 | — |
| VIKRAMTHVikram Thermo | — | — | — | ₹728 Cr | — | — |
| ZIMLABZim Laboratories | ₹133.50 | +2.30% | +92.4% | ₹715 Cr | 112.2 | — |
| VALIANTLABValiant Laboratories | ₹131.05 | −2.00% | +56.4% | ₹712 Cr | — | — |
| AMANTAAmanta Healthcare | ₹182.55 | −3.26% | +37.4% | ₹709 Cr | 42.2 | — |
| GAUDIUMIVFGaudium IVF and Women Health | ₹95.11 | +1.07% | — | ₹692 Cr | 24.3 | — |
| WANBURYWanbury | ₹185.66 | −0.42% | −25.7% | ₹649 Cr | 9.6 | — |
Ask anything about Gaudium IVF and Women Health
Pivot answers on the live chart with evidence you can check, and tests strategies against GAUDIUMIVF's own history. Try: “Why has GAUDIUMIVF moved over the last three months?” · “Backtest a 50-day moving-average crossover on GAUDIUMIVF over five years” · “Compare GAUDIUMIVF with KILITCH on margins and valuation”
Frequently asked questions about Gaudium IVF and Women Health
What is the share price of Gaudium IVF and Women Health today?
Gaudium IVF and Women Health (NSE: GAUDIUMIVF) last closed at ₹95.11 on 22 Oct 2026. Its 52-week high is ₹163.18 and its 52-week low is ₹69.18.
What is the market cap of Gaudium IVF and Women Health?
Gaudium IVF and Women Health's market capitalisation is ₹692 Cr (₹692 Cr) at the 22 Oct 2026 close, ranking 1635th among the NSE companies Pivot tracks.
What is the P/E ratio of Gaudium IVF and Women Health?
Gaudium IVF and Women Health trades at a trailing P/E of 24.3. The median P/E of the 4 closest Pharma & Healthcare peers by market cap is 42.2.
What is the ROE and ROCE of Gaudium IVF and Women Health?
Return on equity was 16.1% in FY26 and return on capital employed was 23.1% in FY26 (consolidated figures).
Is Gaudium IVF and Women Health a debt-free company?
No. Gaudium IVF and Women Health's debt-to-equity ratio was 0.15 in FY26, with total debt of ₹0 Cr.
What were Gaudium IVF and Women Health's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Gaudium IVF and Women Health reported revenue of ₹30 Cr, +12.7% year on year, and net profit of ₹8 Cr, +29.6% year on year.
What is the shareholding pattern of Gaudium IVF and Women Health?
As of 30 Jun 2026: promoters 71.29%, foreign institutions 3.02%, domestic institutions 2.22%, non-institutions 23.47%.
Who are Gaudium IVF and Women Health's competitors?
The listed Pharma & Healthcare companies closest to Gaudium IVF and Women Health by market cap are Kilitch Drugs (India), Vikram Thermo, Zim Laboratories, Valiant Laboratories, Amanta Healthcare and Wanbury.
Is Gaudium IVF and Women Health a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Gaudium IVF and Women Health's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GAUDIUMIVF against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text